Team
Simon Jäger
Specialist in Internal Medicine
Specialist in Clinical Pharmacology

Dr. Simon Jäger


Tel +49-711-8101 2090

Major Projects

  • Implementation of pharmacogenetics into the clinic
  • Conduct and design of clinical studies 
  • “MOBILISE-D” (2020-JTI-IMI2-2017-13): Linking digital assessment of mobility to clinical endpoints to support regulatory acceptance and clinical practice
  • “NETZ” Endoscopic telemedicine service for improving colorectal cancer prevention“ (Federal Ministry of Education and Research, Germany)
  • POLAR_MI: „POLypharmazie, Arzneimittelwechselwirkungen und Risiken“ Medizininformatik-Initiative (MII)
  • TAMENDOX: Machbarkeitsnachweis der Supplementierung einer Standard-TAMoxifentherapie mit dem aktiven Metaboliten ENDOXifen

Selected References

Simon U Jaeger, Martin Wohlrab, Daniel Schoene, Roman Tremmel, Michael Chambers, Letizia Leocani, Solange Corriol-Rohou, Jochen Klenk, Basil Sharrack, Judith Garcia-Aymerich, Lynn Rochester, Walter Maetzler, Milo Puhan, Matthias Schwab, Clemens Becker. Mobility endpoints in marketing authorisation of drugs: What gets the European medicine agency moving? Age and Ageing. 2022 Jan 6;51(1):afab242. doi: 10.1093/ageing/afab242
J Heitmann, T Bilich, C Tandler, A Nelde, Y Maringer, M Marconato, J Reusch, SU Jaeger, … , HG Rammensee, H Salih, J Walz. Phase I Trial of a Multi-Peptide COVID-19 Vaccine for the Induction of SARS-CoV-2 T-Cell Immunity. Nature (2021). 10.1038/s41586-021-04232-5
Jäger Simon, Schricker Severin, Tremmel Roman, Schaeffeler Elke, Schwab Matthias. Praxisrelevante pharmakogenetische Diagnostik zur Verbesserung der Arzneimitteltherapie: Erratum. Dtsch Med Wochenschr. 2021;146(1):e21. doi: 10.1055/a-1346-4382. PMID: 33412591.
Möllers Tobias, Schwab Matthias, Gildein Lisa, Hoffmeister Michael, Albert Jörg, Brenner Hermann, Jäger Simon. Second-generation colon capsule endoscopy for detection of colorectal polyps: Systematic review and meta-analysis of clinical trials. Endoscopy Int Open. 2021;9(4):E562-E571. doi: 10.1055/a-1353-4849. PMID: 33860073.
Just Katja S, Dormann Harald, Böhme Miriam, Schurig Marlen, Schneider Katharina L, Steffens Michael, Dunow Sandra, Plank-Kiegele Bettina, Ettrich Kristin, Seufferlein Thomas, Gräff Ingo, Igel Svitlana, Schricker Severin, Jaeger Simon U, Schwab Matthias, Stingl Julia C. Personalising drug safety-results from the multi-centre prospective observational study on Adverse Drug Reactions in Emergency Departments (ADRED). Eur J Clin Pharmacol. 2019;. doi: 10.1007/s00228-019-02797-9. PMID: 31832731.
Abdel-Kahaar Emaad, Winter Stefan, Tremmel Roman, Schaeffeler Elke, Olbricht Christoph J, Wieland Eberhard, Schwab Matthias, Shipkova Maria, Jaeger Simon U. The Impact of CYP3A4*22 on Tacrolimus Pharmacokinetics and Outcome in Clinical Practice at a Single Kidney Transplant Center. Frontiers in genetics. 2019;10:871. doi: 10.3389/fgene.2019.00871. PMID: 31616470.
Schaeffeler, Elke; Jaeger, Simon U.; Klumpp, Verena; Yang, Jun J.; Igel, Svitlana; Hinze, Laura et al. (2019): Impact of NUDT15 genetics on severe thiopurine-related hematotoxicity in patients with European ancestry. Genet Med 149, 907. 10.1038/s41436-019-0448-7
Jaeger, Simon U.; Klag, Thomas; Hoeger, Katharina; Klumpp, Siegfried; Escher, Markus; Malek, Nisar et al. (2019): Tacrolimus Suppositories in Therapy-Resistant Ulcerative Proctitis. Inflamm Intest Dis. 2019 Feb;3(3):116-124. doi: 10.1159/000493979
Jaeger Simon U, Schaeffeler Elke, Winter Stefan, Tremmel Roman, Schölmerich Jürgen, Malek Nisar, Stange Eduard F, Schwab Matthias, Wehkamp Jan. Influence of NOD2 Variants on Trichuris suis ova Treatment Outcome in Crohn's Disease. Front Pharmacol. 2018;9:764. doi: 10.3389/fphar.2018.00764. PMID: 30061834.
Hünerwadel, A; Fagagnini, S; Rogler, G; Lutz, C; Jaeger SU; Mamie C. et al. (2018): Severity of local inflammation does not impact development of fibrosis in mouse models of intestinal fibrosis. Sci Rep Oct 12;8(1):15182. doi: 10.1038/s41598-018-33452-5
Jager S, Stange E F, Wehkamp J. Inflammatory bowel disease: An impaired barrier disease. Langenbecks Arch Surg. 2013;398(1):1-12.
Jaeger, S. U.; Schroeder, B. O.; Meyer-Hoffert, U.; Courth, L.; Fehr, S. N.; Gersemann, M. et al. (2013): Cell-mediated reduction of human β-defensin 1. A major role for mucosal thioredoxin. Mucosal immunology 6 (6), 1179–1190. 10.1038/mi.2013.17
Kuchler R, Schroeder B O, Jaeger S U, Stange E F, Wehkamp J. Antimicrobial activity of high-mobility-group box 2: A new function to a well-known protein. Antimicrob Agents Chemother. 2013;57(10):4782-4793. doi: 10.1128/AAC.00805-13.
Hofmann U, Heinkele G, Angelberger S, Schaeffeler E, Lichtenberger C, Jaeger S, Reinisch W, Schwab M. Simultaneous quantification of eleven thiopurine nucleotides by liquid chromatography-tandem mass spectrometry. Anal Chem. 2012;84(3):1294-1301.

Curriculum Vitae

Education and Professional Career

Since 2021

Specialist in Clinical Pharmacology and Group leader

2021

Board Certification in Clinical Pharmacology

Since 2021

Collaboration with Clinical Cooperation Unit Translational Immunology, University Hospital Tuebingen

Since 2020

Studies of Medical Biometry/Biostatistics (Master of Science), University of Heidelberg, School of Medicine, Heidelberg, Germany

2019-2021

Resident in Clinical Pharmacology and Postdoctoral Research Fellow (Prof. Dr. med. M. Schwab), University Hospital Tuebingen, University of Tuebingen, Germany

2017-2021

Resident in Clinical Pharmacology and Postdoctoral Research Fellow (Prof. Dr. med. M. Schwab), Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology, Stuttgart

2017

Board Certificate in Internal Medicine

2017

Research Grant from Robert Bosch Stiftung, Project Title: „The balance between hypoxia-induced autophagy and NLRP3 activation is shifted towards inflammation in inflammatory bowel disease” at Universitäts-Spital Zürich, Clinical of Gastroenterology (Prof. Dr. med. Dr. phil. Gerhard Rogler)

2011

ECFMG Certificate

2010-2012

Research Grant from DFG and Robert Bosch Stiftung (Gerok Program), Project Title: “Regulation of the redox status of hBD-1 (humanes ß-Defensin 1) in inflammatory bowel disease

2009

Doctoral Thesis "Surveillance des Barrett-Ösophagus – Vergleich konservative Therapie versus Anti-Reflux-Operation“, (Prof. Dr. med. M. Fein, Surgical University Clinic, University of Würzburg, Germany)

2008-2017

Training in Internal Medicine, Robert Bosch Krankenhaus, Investigator in 13 clinical trials in the field of inflammatory bowel disease

2001-2008

Studies in Human Medicine at the University of Würzburg, Germany, University of Rochester, USA, and University of Buenos Aires, Argentina

Research Group

Drug Information & Patient care